


Summary

Name	CD48/SLAMF2/SLAM Family Member 2/BCM1/BLAST1
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/μg as determined by LAL test.
Construction	Recombinant Human SLAM Family Member 2 is produced by our Mammalian expression system and the target gene encoding Gln27-Ser220 is expressed with a human IgG1 Fc, 6His tag at the C-terminus.
Accession #	P09326
Host	Human Cells
Species	Human
Predicted Molecular Mass	50.3 KDa
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

SDS-PAGE image



Background

Alternative Names CD48 antigen; B-lymphocyte activation marker BLAST-1; BCM1 surface antigen;

Product Name: Recombinant Human SLAMF2 (C-Fc-6His)
Catalog #: PHH0139



Background

Leukocyte antigen MEM-102; TCT.1; CD48; BCM1; BLAST1
CD48 antigen, also known as B-lymphocyte activation marker BLAST-1, BCM1 surface antigen, Leukocyte antigen MEM-102, TCT.1, CD48, BCM1, and BLAST1, CD48 contains one Ig-like C2-type domain and one Ig-like V-type domain, but does not have a transmembrane domain, however, it is held at the cell surface by a GPI anchor via a C-terminal domain which may be cleaved to yield a soluble form of the receptor. CD48 may facilitate interaction between activated lymphocytes and be involved in regulating T-cell activation. CD48 plays a vital role as an environmental sensor for regulating progenitor cell numbers and inhibiting tumor development. It is suggested that the anti-CD48 mAb has the potential to become an effective therapeutic mAb against multiple myeloma.

Note

For Research Use Only , Not for Diagnostic Use.